Skip to content
BCP92™ Bacillus Coagulans Probiotic | 150 Billion CFU/g, Heat Stable | Wholesale Probiotic Supplier
Wholesale Ingredient

Clinically Studied Bacillus Coagulans Spore Probiotic

BCP92™ is a spore-forming Bacillus coagulans probiotic powder standardized to 150 billion CFU/g. It is heat stable, needs no refrigeration, and is backed by randomized, double-blind, placebo-controlled human studies, a published whole genome, and an FDA GRAS notice for use in foods and beverages.

150 Billion CFU/g
Heat Stable
No Refrigeration
FDA GRAS Notice
Published Human RCTs
Typical response: 1 business day • Samples, specs, and pricing available upon request
The Ingredient

What is BCP92™?

BCP92™ is a single, fully characterized strain of Bacillus coagulans (also classified as Heyndrickxia coagulans), supplied as a spray-dried spore powder standardized to 150 billion CFU/g. Unlike conventional probiotic cultures, BCP92™ is delivered as dormant spores with a natural protective coat. That is why it holds up through heat processing, ambient storage, and stomach acid, and why it works in formats where most probiotics cannot.

Spore Forming and Heat Stable

BCP92™ spores stay dormant until they reach the gut. In published testing the strain held its viable count through hot beverages at 80 to 85 °C, gummy depositing, and baking at 175 °C, and through 180 days of storage in finished foods. No cold chain is required.

Clinically Studied in Humans

Two published randomized, double-blind, placebo-controlled trials cover both ends of the digestive health spectrum: a 12-week study in 100 adults with irritable bowel syndrome and a 42-day study in healthy adults. A third human study on protein absorption is underway.

Genome Sequenced and Safety Tested

The complete 3.48 Mb genome is published. Analysis found no virulence genes, no toxin genes, no antibiotic resistance genes, and no plasmids. Acute and 28-day oral toxicity studies support the safety profile, with a NOAEL of 1,000 mg/kg/day.

Built for Foods, Beverages, and Supplements

At 150 billion CFU/g, a clinically studied serving is only a few milligrams of powder. BCP92™ blends directly into capsules, tablets, gummies, stick packs, hot and cold beverages, baked goods, and chocolate without reformulating around the probiotic.

The Spore Advantage

Survives the process. Survives the stomach.

A probiotic only works if it arrives alive. Most cultures lose viability twice: once in manufacturing and storage, and again in stomach acid. BCP92™ spores are built to get through both.

Through Manufacturing and Shelf Life
Heat, Moisture & Time

The spore coat protects BCP92™ from heat, low water activity, and acidic conditions that kill vegetative probiotic cells. Published food matrix studies show no significant loss of viable count through hot-fill, cooking, and baking, or over six months in finished products.

  • Stable in hot tea and coffee at 80 to 85 °C
  • Tolerates gummy processing and baking
  • Ambient storage, no cold chain
  • Genetically stable from seed culture to final product
Through the Digestive Tract
Acid & Bile Tolerance

BCP92™ tolerates gastric acid and bile salts, then germinates in the intestine. Its genome carries 29 stress-response genes along with genes for adhesion, lactic acid production, and bacteriocin synthesis, the traits that define a functional probiotic.

  • Resists stomach acid and bile salts
  • Produces lactic acid
  • Carries genes for a circular bacteriocin
  • Adhesion genes that support gut residence

The Dose on the Label Is the Dose Delivered

Because BCP92™ is stable through processing and shelf life, formulators can build around a real CFU target instead of heavy overages and refrigerated logistics. One ingredient covers shelf-stable supplements and functional foods alike.

Clinical Evidence

12 weeks. Placebo controlled. Statistically significant.

Published in Medicine (2024), the lead BCP92™ trial enrolled 100 adults with irritable bowel syndrome at two clinical centers and randomized them to 2 billion CFU of BCP92™ or placebo once daily for 12 weeks. Outcomes were measured with validated instruments including the IBS Severity Scoring System, the Digestive Symptom Frequency Questionnaire, the Bristol Stool Form Scale, and the Perceived Stress Scale. All 100 participants completed the study.

BCP92™ vs. Placebo
% Change from Baseline / Week 12
n = 100, RCT
Symptom Severity (IBS-SSS) −59% vs −5%
−59%
−5%
Bowel Irregularity Frequency −58% vs −13%
−58%
−13%
Bloating or Cramping Frequency −54% vs −6%
−54%
−6%
Abdominal Discomfort Frequency −53% vs −13%
−53%
−13%
Perceived Stress (PSS) −22% vs −8%
−22%
−8%
BCP92™ 2 billion CFU
Placebo

Percent change calculated from published group means at baseline and week 12.

Study Highlights

  • Symptom Severity
    Mean IBS-SSS fell from 341 at baseline to 139 at week 12 in the BCP92™ group, moving from the severe range to the mild range. Placebo was essentially unchanged, 297 to 282 (P<0.001 between groups).
  • Bloating & Abdominal Comfort
    Frequency of bloating or cramping, abdominal pain, stomach rumbling, and nausea all improved significantly versus placebo (P<0.001 for each).
  • Stool Consistency
    Stool form on the Bristol scale shifted significantly toward normal by week 12 in the BCP92™ group (P<0.001).
  • Gut and Mind
    Perceived Stress Scale scores dropped from 25.3 to 19.8 with BCP92™, a significant difference versus placebo at end of treatment (P=0.001).
  • Clean Safety Profile
    No serious or treatment-emergent adverse events. Hematology, liver, and kidney markers stayed in the normal range, and there were no dropouts.
Shaikh SS, Kumar S. Role of Bacillus coagulans (Heyndrickxia coagulans) BCP92 in managing irritable bowel syndrome: a randomized, double-blind, multicenter, placebo-controlled clinical trial. Medicine, 2024;103(31):e39134. DOI 10.1097/MD.0000000000039134. CTRI/2023/03/051167.

The rest of the BCP92™ research file

Human RCT

Healthy Adult Gut Microbiome

A 42-day randomized, double-blind, placebo-controlled study in 48 healthy adults at 1 billion CFU per day. BCP92™ was well tolerated, left overall microbiome composition intact, and was associated with subtle favorable shifts and a slight rise in fecal short-chain fatty acids.

  • Medicine, 2026;105(35):e50435
  • CTRI/2024/04/066125
Preclinical

Digestive and Gut-Brain Models

In a standard digestive challenge model, BCP92™ inhibited stool output by 36% and 52% at low and high doses. In a separate six-week stress model, it raised serotonin and BDNF, lowered inflammatory markers, and increased fecal short-chain fatty acids.

  • Toxicology Research, 2024;13(6):tfae182
  • Gut-brain axis study, 2025
Safety & Genomics

Characterized Down to the Genome

Whole genome sequencing confirmed strain identity (99.61% 16S rRNA homology to the type strain) and screened for risk genes. Toxicology found no adverse effects at 2,000 mg/kg acute or 1,000 mg/kg/day over 28 days, and no cytotoxicity in cell assays.

  • Letters in Applied Microbiology, 2024;77(1):ovad145
  • OECD 420 and OECD 407 protocols

A third human trial, evaluating protein absorption and muscular strength in 34 resistance-trained men over 60 days, is registered as CTRI/2026/02/104757. Results are pending.

Stability Data

Tested in real food and beverage systems.

BCP92™ at 150 billion CFU/g was added directly to finished foods and beverages, then counted before and after processing and across 180 days of storage. Viable counts showed no statistically significant decline in any matrix tested.

After Processing
Relative viability / heat exposure
98.14 to 99.97%
Tea80 to 85 °C, 30 min
99.97%
Cerealhot milk, 5 min
99.78%
Gummiesmixed at 85 to 90 °C
99.67%
Instant coffee80 to 85 °C, 30 min
99.45%
Soup80 to 85 °C, 30 min
99.36%
Oatmeal80 to 85 °C, 30 min
98.81%
Browniesbaked at 175 °C, 22 to 25 min
98.14%
After 180 Days of Storage
Relative viability / finished product
98.40 to 100%
White chocolate4 °C
100%
Milk chocolate4 °C
99.99%
Ice cream−20 °C
99.41%
Cold coffee4 °C
99.23%
Dark chocolate4 °C
99.16%
Fruit juice4 °C
98.87%
Energy drink4 °C
98.74%
Peanut butterroom temperature
98.40%
Relative viability is the published ratio of log10 viable counts after versus before each condition; selected matrices shown. Shaikh SS, et al. Food Storage, Processing and Genetic Stability Studies of Bacillus (Heyndrickxia) coagulans BCP92 (MTCC 25460). Applied Food Biotechnology, 2024;11(1):e22. Results in your formula will depend on the matrix, process, and packaging.
Why Formulators Choose BCP92™

A documented strain, not a commodity culture.

Probiotic benefits are strain specific. Much of the Bacillus coagulans on the market is sold by species name alone, with no clinical work on the material in the drum. BCP92™ comes with its own human trials, genome, toxicology, and stability file.

150 Billion CFU/g Potency

A concentrated spore powder means a very small inclusion rate, leaving room in the capsule, gummy, or stick pack for the rest of the formula.

  • 1 billion CFU in about 7 mg
  • 2 billion CFU in about 13 mg
  • Minimal impact on taste and texture

No Cold Chain

BCP92™ ships and stores at ambient temperature. That removes refrigerated freight, cold storage, and the viability losses that come with temperature excursions.

  • Ambient shipping and warehousing
  • Shelf-stable finished products
  • Suited to e-commerce and retail

Published Human RCTs

Two peer-reviewed, randomized, double-blind, placebo-controlled trials run on this exact strain, with a third human study in progress.

  • 100-subject, 12-week digestive trial
  • Healthy adult microbiome trial
  • Validated instruments, CTRI registered

Regulatory Ready

The subject of FDA GRAS Notice GRN 1159, which closed with an FDA "no questions" letter for use in a broad range of conventional foods at up to 2 billion CFU per serving.

  • FDA GRAS notice, no questions letter
  • Health Canada product licence
  • Species on the EFSA QPS list

Fully Characterized Strain

Identity is confirmed by 16S rRNA and whole genome sequencing, and the strain is deposited in a recognized culture collection so you can name it on the label.

  • Culture collection deposit MTCC 25460
  • Published whole genome sequence
  • Genetic stability confirmed by DNA fingerprinting

Clean Label Credentials

Made without animal-origin components and free from major allergens, with documentation ready for your quality team.

  • Kosher and Halal certified
  • Allergen free, no animal-origin inputs
  • FSSC 22000 and GMP certified production
BCP92™ vs. The Rest

How BCP92™ compares to other probiotic options.

Conventional probiotic cultures bring strong consumer recognition but are fragile in processing and storage. Generic spore formers are hardy but often undocumented. See how BCP92™ compares on the points formulators evaluate.

Feature BCP92™ Generic Bacillus Coagulans Lactobacillus / Bifidobacterium
Form Dormant spores Dormant spores Live vegetative cells
Human RCTs on This Strain Yes, two published Often none Varies by strain
Published Genome & Safety File Yes Varies Varies by strain
FDA GRAS Notice Yes, GRN 1159 Strain dependent Strain dependent
Refrigeration Not required Not required Often required
Hot Beverages & Baking Tested and stable Likely, rarely documented Generally unsuitable
Stomach Acid Tolerance High High Low to moderate
Typical Potency 150 billion CFU/g Variable Variable, declines in storage
Comparison based on typical commercial offerings. Specific performance depends on the strain, finished product, dose, and storage conditions.
Formulating With BCP92™

A probiotic for formats that used to be off limits.

BCP92™ is a free-flowing powder with a milligram-level serving size. It blends directly into dry mixes and tolerates the heat steps that rule out conventional cultures.

Capsules & Tablets
Shelf stable at room temperature
Probiotic Gummies
Tested through gummy processing
Stick Packs & Powders
Greens, protein, hydration blends
Coffee & Tea
Stable in hot water at 80 to 85 °C
Juices & Functional Drinks
180-day data in juice and energy drinks
Baked Goods & Bars
Tested through baking at 175 °C
Chocolate & Confections
Full viability at 180 days
Cereals, Oats & Soups
Holds up to cooking and hot prep
Studied Daily Dose
1 to 2 billion CFU
At 150 billion CFU/g, that is roughly 7 to 13 mg of BCP92™ per serving before any overage. Human studies used once-daily dosing for 6 to 12 weeks. GRAS use in conventional foods covers up to 2 billion CFU per serving.
Consumer Benefits

Five stories you can tell on pack.

Each one grounded in the published BCP92™ research.

Digestive Comfort
Supports everyday gut comfort
Less Occasional Bloating
Lower bloating frequency in study
Regularity
Supports healthy stool consistency
Gut-Brain Connection
Lower perceived stress scores
Gentle Daily Use
Well tolerated in human trials

Ready to add a clinically studied probiotic to your next SKU?

Whether you are building a daily probiotic capsule, a gut health gummy, a functional coffee, or a better-for-you snack, BCP92™ gives you one shelf-stable, documented strain to anchor the claim.

  • 150 billion CFU/g spore powder
  • Heat stable, no refrigeration required
  • Two published human RCTs and an FDA GRAS notice
  • Technical and regulatory documents from our San Diego team
Talk to our team

Request samples, the specification sheet, the published studies, and pricing. Our team will help you scope target CFU, format, and claim language.

Talk to Sales Email sales@selectingredients.com
Typical response: 1 business day
Samples, specs, and pricing available upon request
FAQ

Frequently Asked Questions

Common questions from R&D, regulatory, and brand teams.

What is BCP92™?

BCP92™ is a single strain of Bacillus coagulans (also classified as Heyndrickxia coagulans), deposited as MTCC 25460 and supplied as a spray-dried spore powder standardized to 150 billion CFU/g. It is a Gram-positive, spore-forming, lactic acid producing probiotic.

Does BCP92™ need refrigeration?

No. BCP92™ is delivered as dormant spores, which are naturally resistant to heat and dry conditions. It ships and stores at ambient temperature, and finished products made with it do not need a cold chain.

What is the clinically studied dose?

Published human trials used 2 billion CFU once daily for 12 weeks in adults with irritable bowel syndrome and 1 billion CFU once daily for 42 days in healthy adults.

How much BCP92™ powder goes into a serving?

At 150 billion CFU/g, 1 billion CFU is about 7 mg of powder and 2 billion CFU is about 13 mg, before any overage you choose to add for shelf life. The small inclusion rate leaves room for the rest of your formula.

What formats does BCP92™ work in?

BCP92™ has published viability data in hot tea and coffee, soups, oatmeal, cereal, gummies, baked brownies, chocolate, ice cream, fruit juice, energy drinks, and peanut butter. It is also well suited to capsules, tablets, stick packs, and powder blends.

Is BCP92™ GRAS?

Yes. BCP92™ is the subject of FDA GRAS Notice GRN 1159, which closed in 2024 with an FDA "no questions" letter. The notice covers use in a broad range of conventional foods and beverages at up to 2 billion CFU per serving.

Is BCP92™ safe?

The strain's whole genome has been sequenced and screened, with no virulence, toxin, or antibiotic resistance genes identified, and it is non-hemolytic. Acute and 28-day repeated-dose oral toxicity studies reported no adverse effects, and no serious adverse events were reported in the published human trials.

What claims can I build on BCP92™?

Structure-function directions supported by the published research include supports digestive health, supports digestive comfort, helps reduce occasional bloating, and supports regularity. Claim language should be reviewed with your regulatory counsel for your product and target market.

What certifications does BCP92™ carry?

BCP92™ is Kosher and Halal certified, allergen free, and made without animal-origin components, in an FSSC 22000 and GMP certified facility. Certificates and full documentation are available on request.

How do I request samples and specs?

Reach out through the Talk to Sales button or email sales@selectingredients.com. Typical response time is one business day. Our San Diego team can provide samples, the specification sheet, the published studies, and pricing.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Information on this page is intended for food, beverage, and dietary supplement manufacturers and is not intended for consumers. Clinical study descriptions summarize published research and are not claims for any finished product.